(€15,398 vs. €8614; pϭ0.016) than patients without these co-morbidities. Indirect costs were also higher in PD patients with these co-morbidities than patients with PD alone; the difference being significant only for dementia (€8201 vs. €2964; pϭ0.037). CONCLUSIONS: Co-morbid dyskinesia, dementia, or depression were observed to be the major contributors to the fiscal burden of PD in Germany, post-2000. An overall increase in the (estimated) costs associated with these co-morbidities was evident during the time-period evaluated. Further studies to understand the cause of increased (estimated) costs associated with these co-morbidities in PD are warranted. 
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12-MONTH COST OF ILLNESS STUDY OF MODERATE ALZHEIMER'S DISEASE PATIENTS IN SPAIN: THE EVOCOST STUDY
Salva
OBJECTIVES:
There is a lack of long-term prospective data to document the economic burden (direct and indirect costs) of Alzheimer's disease (AD), especially in moderate AD where disease management becomes more complex. The EVOCOST study aims to describe and analyse the health care resource use and costs associated with clinical evolution in a cohort of moderate AD patients in routine medical practice in Spain. METHODS: The EVOCOST study is a prospective 12-month multicentre cohort study recruiting community-dwelling moderate AD patients in Spain. Health care resources (specialist, general practitioner and nurses visits, hospitalisations and emergency room visits, antidementia drugs and institutionalisation) and non-health care resources (caregiver's time for care and supervision) were collected retrospectively. Total costs over the entire 12-month study follow-up were calculated. Costs over the 3 months preceding baseline and the end of follow-up were compared. RESULTS: A total of 209 patients were included at baseline, 76.1% of them were women, with a mean age of 78.4 years and a mean MMSE of 15.2. Over the entire 12-month study follow-up, the mean monthly cost per patient was €1016 (annual cost €12197). The major cost driver was the informal caregiver time dedicated to patient supervision and care (€852, 84% of total cost). Other costs were as follows: antidementia drugs (€88, 9%), hospitalisation and emergency room visits (€31, 3%), visits (€26, 3%) and institutionalisation (€20, 2%).The mean monthly cost per patient increased significantly during the 12-month study follow-up from €902 to €1074 (⌬costϭϩ19%, pϽ0.001), mainly due to the increase in caregiver time. CONCLUSIONS: Management of community-dwelling moderate AD patients in Spain is associated with a high monthly cost (Ͼ €1000/ month). The main cost driver is by far the caregiver time which is not reimbursed by health insurance. The EVOCOST study results illustrate the economic burden of Alzheimer's disease on patients' caregivers. Multiple sclerosis (MS) is a multifocal central nervous system disorder characterised by inflammatory demyelinating lesions affecting white and grey matter. MS affects quality of life of the patients and requires costy and long term treatments. OBJECTIVES: To determine the direct medical costs incurred in the treatment of relapsing remitting MS patients in the Social Security Mexican Institute (IMSS).
PND21 MULTIPLE SCLEROSIS IN RUSSIAN FEDERATION: EVALUATION OF SOCIAL AND ECONOMICAL BURDEN IN REAL CLINICAL PRACTICE
PND22 DESCRIPTIVE ANALYSIS OF THE DIRECT COSTS OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE MEXICAN SETTING
METHODS:
The data for this analysis were abstracted from the IMSS records, to be included each patient had to have at least 1 medical claim with a diagnosis of MS between January 1, 2008 and December 31, 2008. The patients records were used to obtain resource utilization over the year (including prescription drugs, clinician visits, surgical procedures, diagnostic procedures, etc), the costs were obtained from the IMSS public lists and were actualized to 2011 costs. RESULTS: A total of 172 patients were identified with a MS code, 52.33% (nϭ90) of them met the criteria for relapsing remitting MS. There were 54 female patients, with a female:male ratio of 1.5:1, with a mean evolution time of 7.21 years. The total average annual cost for each patient was MxP $173.970,64, 81.31% of which was attributable to the cost of prescription drugs, (80.5% was associated to the cost of disease-modifying drugs in particular (including interferon beta 1b, interferon beta 1a and glatiramer acetate); 16.2% to outpatient care (diagnostic and treatment-related procedures, office visit charges for usual care), 1.3% to inpatient care (diagnostic or treatment-related procedures, room and board charges, clinician inpatient visit and surgical procedures) and 1.16% to emergency room care (associated to disease exacerbation mainly). CONCLUSIONS: This analysis shows that prescription drug accounted for 81.31% of total relapsing-remitting MS related medical direct costs in the Mexican setting and that this costs are mainly associated with the use of disease-modifying drugs. 
PND23 ECONOMIC BURDEN OF ILLNESS FOR PERSONS WITH SPINA BIFIDA (SB) IN GERMANY
OBJECTIVES:
To describe economic burden for persons with SB in Germany. METHODS: Survey data were used to capture use of health care and assistive technologies for both last year and ten years prior to data collection. Participants were recruited from the tertiary clinic database or when initiating care in the clinic. Participants had to have a verifiable SB diagnosis, and a cognitive ability to respond to the questionnaire or a caregiver able to answer questions. Data were doubleentered with queries issued to patients to improve data quality. Descriptive analyses were used to summarize data. RESULTS: Information on resource use for 88 participants was collected (44% female, mean age 28.7, SDϭ13.5). In the year prior to data collection, 88.6% (Nϭ78) had at least one visit to a general practitioner (GP), 77.3% (Nϭ68) a visit to urologist, and 69.3% (Nϭ61) a visit to physiotherapist. Mean number of annual visits was 7.6 GP, 3.6 urologist, and 65.3 physiotherapist visits. Participants reporting secondary care use were found to visit hospital most often (Nϭ38, 43.2%), followed by emergency room care (Nϭ12, 13.6%). Among responders being hospitalized, average annual length of stay in a regular ward was 14.8 days per person, with average hospitalization of 7.3 days. During previous ten years, majority of responders required a wheelchair (Nϭ59, 67.0%), glasses (Nϭ57, 64.7%), and orthopaedic shoes (Nϭ52, 59.1%), with an average of 2.5, 2.8, and 6.1 new items respectively. CONCLUSIONS: Results indicate that persons with SB require a substantial amount of health care both in short and long term and that the overall burden experienced by persons with SB may be high, especially if coupled by possible quality of life implications. Successful prevention, using education and targeted intervention for women of childbearing age could reduce the burden, but further research is required to fully understand economic impact of SB.
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